KG Saag, GG Teng, NM Patkar, J Anuntiyo, C … - Arthritis Rheum, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 128 - Related articles - All 2 versions
M Weinblatt, B Combe, A Covucci, R Aranda, … - Arthritis Care & Research - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 122 - Related articles - BL Direct - All 3 versions
- ►kup.at [PDF] JS Smolen, A Beaulieu, A Rubbert-Roth, C … - The Lancet, 2008 - Elsevier In this double-blind, randomised, placebo-controlled, parallel group phase III
study, 623 patients with moderate to severe active rheumatoid arthritis were
randomly assigned with an interactive voice response system, stratified by ... Cited by 100 - Related articles - All 16 versions
JS Smolen, D Aletaha, M Koeller, MH … - The Lancet, 2007 - Elsevier Rheumatoid arthritis is characterised by pain, swelling, and destruction of
joints, with resultant disability. Only disease-modifying antirheumatic drugs
can interfere with the disease process. In the past few years, biological ... Cited by 101 - Related articles - All 8 versions
DE Furst, FC Breedveld, JR Kalden, JS … - British Medical Journal, 2007 - ard.bmj.com As in previous years, the consensus group to consider the use of biological
agents was constituted by rheumatologists from the universities of Erlangen,
Leiden and Vienna in Europe in cooperation with other universities in the ... Cited by 78 - Related articles - BL Direct - All 5 versions
DE Furst, FC Breedveld, JR Kalden, JS … - British Medical Journal, 2006 - ard.bmj.com As in previous years, the consensus group to consider the use of biological
agents was constituted by rheumatologists from the universities of Erlangen,
Leiden, and Vienna in Europe in cooperation with other universities in the ... Cited by 58 - Related articles - BL Direct - All 5 versions
- ►nih.gov M Schiff, M Keiserman, C Codding, S … - British Medical Journal, 2008 - ard.bmj.com Results: Similar patient demographics and clinical characteristics were present
at baseline between groups, with mean scores of 1.7 for HAQ-DI and 6.8 for DAS28
(ESR). At 6 months, mean changes in DAS28 (ESR) were significantly greater ... Cited by 49 - Related articles - All 9 versions
- ►nih.gov [PDF] C Salliot, M Dougados, L Gossec - British Medical Journal, 2009 - ard.bmj.com Background: Tumour necrosis factor blockers in rheumatoid arthritis are known to
increase the risk of serious infections defined as life-threatening, requiring
hospitalisation or intravenous antibiotics. Recently, new biological agents ... Cited by 37 - Related articles - All 7 versions
DE Furst, EC Keystone, B Kirkham, R … - British Medical Journal, 2008 - ard.bmj.com As in previous years, the consensus group to consider the use of biological
agents in the treatment of rheumatic diseases met during the 10th Annual
Workshop on Advances in Targeted Therapies. The group consisted of ... Cited by 29 - Related articles - All 6 versions
- ►oxfordjournals.org T Pincus, MJ Bergman, Y Yazici, P Hines, K … - Rheumatology, 2008 - Br Soc Rheumatology Objectives. To analyse the capacity of routine assessment of patient index data
3 (RAPID3), an index of only the three patient-reported outcome (PRO) measures
in the RA Core Data Set—physical function, pain and global status—to ... Cited by 23 - Related articles - BL Direct - All 7 versions
